Skip to main content
. 2017 Dec 8;9(4):4661–4674. doi: 10.18632/oncotarget.23163

Figure 3. Immunostaining patterns of sunitinib sensitive and resistant tumors.

Figure 3

(A) COX-2 is increased in resistant tumors compared to control and sensitive ones. E-cadherin (B) and PAX8 (C) showed reduced staining in resistant tumors compared with control and sensitive tumors.